Individual Stock News REGINA MIRACLE (02199.HK): The interim performance revenue is approximately HKD 3.978 billion, a year-on-year increase of 12.2%, with a net profit of HKD 67.619 million, a year-on-year decrease of 36.7%. Kingkey Financial International (01468.HK): Announced interim results with a profit attributable to owners of HKD 6.806 million, a year-on-year decrease of 91.12%. Chengdu Expressway (01785.HK): Chengwenqiong Expressway Company signed a land acquisition and demolition agreement with the government of Wenjiang District. SINO BIOPHARM (01177.HK): The indication for Bemarituzumab injection combined with Anlotinib hydrochloride capsules for the treatment of endometrial cancer has been approved for market launch. CMS (00867.HK): The innovative drug GLP-1R/GCGR dual agonist CMS-D005 has received a clinical trial approval notice. Shengyang Group (08163.HK): Completed the issuance of convertible securities with a principal amount of HKD 101 million. Laikang Pharmaceutical-B (02105.HK) completed the placement of 17.636 million shares, raising approximately HKD 230 million. Hansoh Pharmaceutical (03692.HK): The fifth indication application for the new lung cancer drug "Amivantamab" has been submitted for market launch. JIUYUAN GENE (02566.HK): The share price is set at HKD 12.42, with the public offering being 675.83 times oversubscribed